Study guide

3.1 Heart Failure GDMT: HFrEF Four Pillars & HFpEF Management

Board Certified Ambulatory Care Pharmacist BCACP

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Overview & Patient Care Process

1.1 BCACP Exam Logistics, Blueprint & Pass Standards 1.2 The Pharmacists' Patient Care Process (PPCP) in Ambulatory Care 1.3 Communication, Health Literacy & Cultural Competence

2 Chapter 2: Cardiovascular I: Hypertension & Dyslipidemia

2.1 Hypertension Guidelines, Staging & Primary Regimens 2.2 Resistant Hypertension, Secondary Causes & Special Populations 2.3 Dyslipidemia: Statin Benefit Groups & Non-Statin Add-ons

3 Chapter 3: Cardiovascular II: Heart Failure, CAD & Anticoagulation

3.1 Heart Failure GDMT: HFrEF Four Pillars & HFpEF Management 3.2 Chronic Coronary Disease & Antiplatelet Strategies 3.3 Anticoagulation: Atrial Fibrillation, VTE & Peri-Procedural Care

4 Chapter 4: Endocrine & Metabolic Disorders

4.1 Type 2 Diabetes: Incretins, SGLT2i & Comorbidity Alignment 4.2 Advanced Diabetes: Insulin Regimens, CGM & Hypoglycemia 4.3 Thyroid & Adrenal Disorders in Ambulatory Care 4.4 Osteoporosis Screening, Prevention & Therapeutic Sequencing

5 Chapter 5: Respiratory Care & Pulmonology

5.1 Asthma Management: GINA/NAEPP Stepwise & SMART Therapy 5.2 COPD Management: GOLD Guidelines & Exacerbation Prevention 5.3 Inhalation Devices, Delivery Techniques & Patient Counseling

6 Chapter 6: Renal, Urological & Reproductive Health

6.1 Chronic Kidney Disease: KDIGO Guidelines & SGLT2i/nsMRA Care 6.2 Benign Prostatic Hyperplasia & Erectile Dysfunction 6.3 Women's Health: Contraception, Menopause & Teratogenicity

7 Chapter 7: Neuropsychiatry & Behavioral Health

7.1 Major Depressive Disorder & Anxiety Disorders 7.2 Bipolar Disorder & Schizophrenia Spectrum 7.3 Epilepsy & Movement Disorders (Parkinson's Disease) 7.4 Migraine Prevention, Acute Treatment & Headache Disorders

8 Chapter 8: Pain Management & Rheumatology

8.1 Chronic Pain, Opioid Stewardship & SUD Management 8.2 Osteoarthritis, Gout & Hyperuricemia 8.3 Rheumatoid Arthritis & Autoimmune Pharmacotherapy

9 Chapter 9: Infectious Diseases & Immunizations

9.1 Ambulatory Infections & Outpatient Antimicrobial Stewardship 9.2 HIV Pharmacotherapy, PrEP/PEP & Viral Hepatitis 9.3 Adult Immunization Schedules & ACIP Recommendations 9.4 Immunizations in Special & High-Risk Populations

10 Chapter 10: Geriatrics, Drug Interactions & Medication Safety

10.1 Geriatric Pharmacotherapy, Beers Criteria & Deprescribing 10.2 Drug Interactions, CYP450, P-gp & Transporters 10.3 Adverse Drug Events, High-Alert Medications & ISMP Safety

11 Chapter 11: Biostatistics, Study Design & Literature Evaluation

11.1 Biostatistical Principles, Hypothesis Testing & Power 11.2 Clinical Study Designs, Bias & Evidence Appraisal 11.3 Pharmacoeconomics: ICER, QALY & Value Metrics

12 Chapter 12: Practice Advancement, Quality & Healthcare Delivery

12.1 Collaborative Practice Agreements & Telehealth Practice 12.2 Quality Improvement, HEDIS & CMS Star Ratings 12.3 Care Transitions, Medication Reconciliation & SDOH 12.4 CMM Services, CPT Coding (99605-99607) & Practice Management 12.5 Clinical Ethics, Patient Advocacy & Conflicts of Interest

3.1 Heart Failure GDMT: HFrEF Four Pillars & HFpEF Management

Key Takeaways Explain This Topic AI

Guideline-Directed Medical Therapy (GDMT) for HFrEF (LVEF ≤40%) comprises four foundational pillars initiated simultaneously or in rapid sequence: an ARNI (sacubitril/valsartan preferred over ACEi/ARB), an evidence-based beta-blocker (metoprolol succinate, carvedilol, or bisoprolol), an MRA (spironolactone or eplerenone), and an SGLT2 inhibitor (empagliflozin or dapagliflozin).

A mandatory 36-hour washout period is required when transitioning from an ACE inhibitor to sacubitril/valsartan to prevent life-threatening bradykinin-mediated angioedema; no washout period is needed when switching from an ARB to an ARNI.

Evidence-based beta-blockers must be initiated only in clinically stable, euvolemic patients at low starting doses and titrated every 2 to 4 weeks to target doses (carvedilol 25–50 mg BID, metoprolol succinate 200 mg daily, bisoprolol 10 mg daily).

SGLT2 inhibitors (empagliflozin 10 mg and dapagliflozin 10 mg daily) reduce cardiovascular death and heart failure hospitalizations across the entire ejection fraction continuum, carrying a Class 1 recommendation for HFrEF and Class 1/2a recommendations for HFmrEF and HFpEF regardless of glycemic status.

Secondary disease-modifying agents include hydralazine/isosorbide dinitrate in self-identified Black patients with persistent NYHA Class III–IV symptoms, ivabradine in sinus rhythm with resting HR ≥70 bpm on maximal beta-blockade, and vericiguat in high-risk patients with recent worsening HF hospitalization.

Last updated: September 2026

3.1 Heart Failure GDMT: HFrEF Four Pillars & HFpEF Management

BCACP Exam Anchor: Heart failure pharmacotherapy represents one of the highest-yield topics on the BCACP examination. Mastery requires deep familiarity with the 2022 AHA/ACC/HFSA Guideline recommendations: rapid quadruple therapy initiation in HFrEF, precise laboratory safety thresholds for MRAs and ARNIs, pharmacokinetic washout intervals, evidence-based beta-blocker selection, and evolving SGLT2 inhibitor indications across all ejection fraction phenotypes.

Heart Failure Phenotypes & Staging Systems

The 2022 AHA/ACC/HFSA guidelines classify heart failure based on left ventricular ejection fraction (LVEF), which dictates specific disease-modifying therapeutic strategies:

HFrEF (Heart Failure with reduced Ejection Fraction): LVEF ≤ 40 % \text{LVEF} \le 40\% LVEF ≤ 40% . Characterized by progressive ventricular dilation and eccentric remodeling. Benefit from all four foundational GDMT pillars.

HFmrEF (Heart Failure with mildly reduced Ejection Fraction): LVEF 41 % to 49 % \text{LVEF } 41\%\text{ to } 49\% LVEF 41% to 49% . SGLT2 inhibitors hold a Class 1/2a recommendation; ARNIs, ACEis/ARBs, and MRAs have Class 2b evidence.

HFpEF (Heart Failure with preserved Ejection Fraction): LVEF ≥ 50 % \text{LVEF} \ge 50\% LVEF ≥ 50% . SGLT2 inhibitors carry a Class 1/2a recommendation to reduce HF hospitalizations; MRAs and ARNIs carry Class 2b/2a recommendations for selected patients.

HFimpEF (Heart Failure with improved Ejection Fraction): Baseline LVEF ≤ 40 % \text{LVEF} \le 40\% LVEF ≤ 40% with a subsequent measurement > 40 % >40\% > 40% (at least a 10-point improvement). Critical Rule: GDMT must be continued indefinitely even if EF normalizes, as medication withdrawal results in high rates of relapse and left ventricular decompensation.

Staging vs. Functional Classification

ACC/AHA Stage Definition Clinical Description NYHA Functional Class (Stage C/D Only)

Stage A: At Risk High risk for HF, no structural heart disease, no symptoms Patients with HTN, DM, atherosclerotic CAD, obesity, metabolic syndrome N/A (Asymptomatic)

Stage B: Pre-HF Structural heart disease present, no HF symptoms Prior MI, LV hypertrophy, reduced LVEF, asymptomatic valvular disease N/A (Asymptomatic)

Stage C: Symptomatic HF Structural heart disease with prior or current HF symptoms Dyspnea, orthopnea, fatigue, peripheral edema, exercise intolerance Class I: No limitation of physical activity; Class II: Slight limitation; comfortable at rest; Class III: Marked limitation; less than ordinary activity causes fatigue/dyspnea; Class IV: Inability to carry on physical activity; symptoms at rest

Stage D: Advanced HF Refractory end-stage HF requiring advanced interventions Recurrent hospitalizations despite maximal GDMT; candidate for LVAD, transplant, or palliative inotropes Class IV: Continuous severe symptoms

The Four Pillars of GDMT in HFrEF (LVEF ≤40%)

The historical paradigm of sequential, slow medication titration over many months has been replaced by the rapid quadruple therapy sequencing model . All four pillars should be initiated simultaneously or in rapid sequence (within 4 to 6 weeks) at low doses, followed by concurrent upward titration to target doses as tolerated.

GDMT Pillar Preferred Agents Starting Dose Target Dose Trial Evidence & Clinical Pearls

1. ARNI (or ACEi / ARB) Sacubitril / valsartan (Entresto) ; ACEi: Lisinopril, Enalapril, Ramipril; ARB: Losartan, Valsartan, Candesartan 24/26 mg or 49/51 mg PO BID; (24/26 mg BID if treatment-naive, low-dose ACEi/ARB, or eGFR <30) 97/103 mg PO BID ; (Lisinopril 20–40 mg QD) ; (Valsartan 160 mg BID) PARADIGM-HF: 20% relative reduction in CV death or HF hospitalization vs enalapril.; PARP-36 Rule: 36-hour washout mandatory when switching from ACEi to ARNI to prevent severe angioedema. ARB to ARNI requires no washout.

2. Evidence-Based Beta-Blocker Carvedilol ; Metoprolol succinate ER ; Bisoprolol ; (Only these 3 agents have proven mortality benefit!) Carvedilol 3.125 mg BID; Metoprolol succinate 12.5–25 mg QD; Bisoprolol 1.25 mg QD Carvedilol 25 mg BID (50 mg BID if >85 kg) ; Metoprolol succinate 200 mg QD ; Bisoprolol 10 mg QD MERIT-HF, COPERNICUS, CIBIS-II: ~34–35% all-cause mortality reduction.; Must initiate only in euvolemic/stable patients. Start low and double every 2–4 weeks. Do not use metoprolol tartrate or atenolol.

3. Mineralocorticoid Receptor Antagonist (MRA) Spironolactone ; Eplerenone Spironolactone 12.5–25 mg QD; Eplerenone 25 mg QD Spironolactone 25–50 mg QD ; Eplerenone 50 mg QD RALES, EMPHASIS-HF: 30% reduction in all-cause mortality.; Safety Criteria: eGFR ≥ 30 mL/min/1.73m 2 \text{eGFR} \ge 30\text{ mL/min/1.73m}^2 eGFR ≥ 30 mL/min/1.73m 2 and K + ≤ 5.0 mEq/L \text{K}^+ \le 5.0\text{ mEq/L} K + ≤ 5.0 mEq/L . Check K+/SCr at 1–2 wks, 4 wks, then q3–6 months.

4. SGLT2 Inhibitor Dapagliflozin ; Empagliflozin Dapagliflozin 10 mg QD; Empagliflozin 10 mg QD Dapagliflozin 10 mg QD ; Empagliflozin 10 mg QD DAPA-HF, EMPEROR-Reduced: 25–26% reduction in CV death or HF hospitalization.; Single fixed dose; no titration needed. Independent of diabetes status. Initiation cutoff: eGFR ≥ 20 to 25 mL/min/1.73m 2 \text{eGFR} \ge 20\text{ to } 25\text{ mL/min/1.73m}^2 eGFR ≥ 20 to 25 mL/min/1.73m 2 .

  • In-Depth Analysis of the Four Pillars
  • Pillar 1: Sacubitril/Valsartan (ARNI)

Mechanism of Action: Sacubitril is a prodrug whose active metabolite (LBQ657) inhibits neprilysin (neutral endopeptidase), preventing the enzymatic degradation of beneficial endogenous vasoactive peptides including atrial natriuretic peptide (ANP), B-type natriuretic peptide (BNP), adrenomedullin, and bradykinin. Valsartan selectively blocks the angiotensin II type 1 ( AT 1 \text{AT}_1 AT 1 ​ ) receptor, mitigating vasoconstriction, aldosterone release, and myocardial fibrosis.

Biomarker Interpretation: Neprilysin breaks down BNP but does not degrade N-terminal pro-B-type natriuretic peptide (NT-proBNP). Therefore, BNP levels increase falsely upon starting sacubitril/valsartan; NT-proBNP is the sole reliable biomarker for assessing clinical congestion and treatment response in patients on an ARNI.

The 36-Hour Washout Rule: Both ACE inhibitors and neprilysin degrade bradykinin. Dual simultaneous inhibition leads to massive bradykinin accumulation and life-threatening angioedema. When switching from an ACE inhibitor to sacubitril/valsartan, clinicians must withhold the ACE inhibitor for a minimum of 36 hours prior to the first ARNI dose. Switching from an ARB to an ARNI carries no bradykinin duplication risk, so no washout interval is required (the next scheduled dose can be sacubitril/valsartan).

Initiation & Titration:

Standard dose switch (from enalapril ≥ 10 mg/day \ge 10\text{ mg/day} ≥ 10 mg/day or lisinopril ≥ 10 mg/day \ge 10\text{ mg/day} ≥ 10 mg/day ): Start 49/51 mg PO BID (sacubitril 49 mg / valsartan 51 mg).

Low-dose switch (from low-dose ACEi/ARB, ACEi/ARB-naive, or eGFR < 30 mL/min/1.73m 2 \text{eGFR} < 30\text{ mL/min/1.73m}^2 eGFR < 30 mL/min/1.73m 2 ): Start 24/26 mg PO BID .

Double the dose every 2 to 4 weeks to achieve the target of 97/103 mg PO BID .

Contraindications: Prior history of angioedema (hereditary, idiopathic, or related to ACEi/ARB), concomitant aliskiren in patients with diabetes, and pregnancy (teratogenic).

Pillar 2: Evidence-Based Beta-Blockers

The Three Proven Agents: Only carvedilol , metoprolol succinate extended-release , and bisoprolol have demonstrated significant reductions in total mortality, sudden cardiac death, and hospitalization in major randomized controlled trials. Immediate-release metoprolol tartrate, atenolol, and propranolol do not have proven mortality benefit in HFrEF and represent unacceptable prescribing errors.

Clinical Distinction:

Carvedilol: Non-selective β 1 / β 2 \beta_1/\beta_2 β 1 ​ / β 2 ​ blocker with α 1 \alpha_1 α 1 ​ -adrenergic antagonism. Produces potent systemic vasodilation and greater blood pressure lowering than β 1 \beta_1 β 1 ​ -selective agents. Must be taken with food to slow absorption and minimize orthostatic hypotension. Target dose: 25 mg BID (or 50 mg BID if body weight > 85 kg >85\text{ kg} > 85 kg ; or carvedilol phosphate CR 80 mg daily).

Metoprolol succinate ER: β 1 \beta_1 β 1 ​ -cardioselective antagonist. Preferred when baseline systolic blood pressure is borderline low or in patients with mild reactive airway disease. Target dose: 200 mg once daily.

Bisoprolol: β 1 \beta_1 β 1 ​ -selective antagonist. Target dose: 10 mg once daily.

Initiation Prerequisites: Patients must be clinically euvolemic and stable (no overt fluid overload or acute decompensation requiring escalating IV diuretics). Beta-blockade acutely reduces inotropy; starting low and titrating slowly prevents transient worsening of congestion. If mild fluid retention occurs during titration, increase the loop diuretic dose temporarily rather than discontinuing the beta-blocker.

Pillar 3: Mineralocorticoid Receptor Antagonists (MRAs)

Mechanism & Benefits: Spironolactone and eplerenone block aldosterone receptors in the distal renal tubule and myocardium, preventing sodium retention, potassium/magnesium wasting, endothelial dysfunction, and myocardial interstitial fibrosis. The RALES (spironolactone) and EMPHASIS-HF (eplerenone) trials demonstrated a 30% reduction in all-cause mortality in HFrEF.

Safety Initiation Thresholds:

Serum Potassium: ≤ 5.0 mEq/L \le 5.0\text{ mEq/L} ≤ 5.0 mEq/L

Renal Function: eGFR ≥ 30 mL/min/1.73m 2 \text{eGFR} \ge 30\text{ mL/min/1.73m}^2 eGFR ≥ 30 mL/min/1.73m 2 (or Serum Creatinine ≤ 2.5 mg/dL \le 2.5\text{ mg/dL} ≤ 2.5 mg/dL in men, ≤ 2.0 mg/dL \le 2.0\text{ mg/dL} ≤ 2.0 mg/dL in women)

Laboratory Monitoring Protocol: Measure serum potassium and renal function at baseline, 1 to 2 weeks , 4 weeks , and every 3 to 6 months thereafter. Withhold or halve MRA therapy if serum potassium rises above 5.5 mEq/L 5.5\text{ mEq/L} 5.5 mEq/L , and discontinue if K + ≥ 6.0 mEq/L \text{K}^+ \ge 6.0\text{ mEq/L} K + ≥ 6.0 mEq/L .

Agent Comparison: Spironolactone is non-selective and interacts with androgen and progesterone receptors, causing gynecomastia, breast tenderness, and menstrual irregularities in ~10% of patients. Eplerenone is a highly selective MRA with minimal affinity for sex steroid receptors (<1% gynecomastia incidence), making it the drug of choice when spironolactone induces endocrine adverse effects.

Pillar 4: SGLT2 Inhibitors

Cardiorenal Mechanisms: Dapagliflozin and empagliflozin inhibit sodium-glucose cotransporter-2 in the proximal renal tubule. In heart failure, their profound benefits operate independently of glycemic control through osmotic diuresis, reduction in preload/afterload, enhanced myocardial energetics (ketone oxidation), improved tubuloglomerular feedback, and attenuation of cardiac fibrosis.

Dosing & Administration: Dapagliflozin 10 mg once daily or Empagliflozin 10 mg once daily . No titration is required. Initiation is permitted down to an eGFR of 20 mL/min/1.73m 2 20\text{ mL/min/1.73m}^2 20 mL/min/1.73m 2 (empagliflozin) or 25 mL/min/1.73m 2 25\text{ mL/min/1.73m}^2 25 mL/min/1.73m 2 (dapagliflozin), with continuation until dialysis initiation.

Adverse Effects & Safety Counseling:

Genital mycotic infections (counsel on daily hygiene).

Transient decline in eGFR (up to 30% initial drop is expected due to restored tubuloglomerular feedback and does not warrant discontinuation).

Volume depletion / hypotension (may allow modest loop diuretic dose reduction).

Euglycemic Diabetic Ketoacidosis (euDKA): Instruct patients to withhold SGLT2i 3 days prior to major elective surgery or during severe acute medical illness/prolonged fasting.

Secondary & Add-On Pharmacotherapy in HFrEF

Medication Mechanism Clinical Indication & Prerequisites Key Dosing & Monitoring

Hydralazine + Isosorbide Dinitrate (H-ISDN) (BiDil) Direct arterial vasodilator (hydralazine) + venous vasodilator / nitric oxide donor (ISDN) 1. Class 1: Self-identified Black patients with persistent NYHA Class III–IV symptoms despite optimal quadruple GDMT (A-HeFT trial).; 2. Class 2a: Patients with severe renal impairment or hyperkalemia unable to tolerate ARNI/ACEi/ARB/MRA. Target: Hydralazine 75 mg / ISDN 40 mg PO TID (BiDil 2 tabs TID).; Adverse effects: Headache, dizziness, GI upset, drug-induced lupus erythematosus (hydralazine).

Ivabradine (Corlanor) Selective hyperpolarization-activated cyclic nucleotide-gated ( I f I_f I f ​ ) funny channel blocker in the SA node Class 2a: Stable symptomatic HFrEF ( LVEF ≤ 35 % \text{LVEF} \le 35\% LVEF ≤ 35% ) in normal sinus rhythm with resting heart rate ≥ 70 bpm \ge 70\text{ bpm} ≥ 70 bpm despite maximally tolerated beta-blocker dose (or BB contraindication). (SHIFT trial). Starting: 5 mg PO BID (2.5 mg BID if age ≥ 75 \ge 75 ≥ 75 or baseline conduction defects).; Target: Titrate to resting HR 50–60 bpm.; Contraindicated in atrial fibrillation, 2nd/3rd degree AV block, acute decompensation. Side effects: Luminous visual phenomena (phosphenes).

Vericiguat (Verquvo) Soluble guanylate cyclase (sGC) stimulator; increases intracellular cyclic GMP Class 2b: High-risk HFrEF ( LVEF < 45 % \text{LVEF} < 45\% LVEF < 45% ) following a recent heart failure hospitalization or outpatient IV diuretic administration within the past 6 months (VICTORIA trial). Starting: 2.5 mg PO QD with food.; Titrate every 2 weeks to target 10 mg PO QD .; Adverse effects: Hypotension, anemia. Teratogenic (contraindicated in pregnancy).

Digoxin Reversible inhibition of myocardial Na + / K + \text{Na}^+/\text{K}^+ Na + / K + ATPase; increases vagal tone and central parasympathetic activity Class 2b: Persistent NYHA Class II–IV symptoms despite GDMT, or for rate control in concomitant AF. Reduces HF hospitalizations without mortality benefit (DIG trial). Narrow Therapeutic Range: Target serum concentration 0.5 to 0.9 ng/mL .; Levels ≥ 1.0 ng/mL \ge 1.0\text{ ng/mL} ≥ 1.0 ng/mL increase mortality.; Signs of toxicity: Nausea, anorexia, visual halos/xanthopsia, ventricular arrhythmias. Toxicity risk heightened by hypokalemia and hypomagnesemia.

Diuretic Therapy & Decongestion Strategies

Loop diuretics are indicated in all HF patients with current or prior fluid retention to restore and maintain euvolemia . Unlike the four foundational pillars, loop diuretics do not reduce mortality, but they relieve congestion, improve functional capacity, and enable the safe uptitration of beta-blockers and ARNIs.

Loop Diuretic Equivalence & Bioavailability

Agent Oral Bioavailability Oral to IV Ratio Equivalent Oral Dose

Furosemide (Lasix) ~50% (variable 10%–90%; delayed absorption with gut edema) 2 : 1 (40 mg PO = 20 mg IV) 40 mg

Torsemide (Demadex) ~80%–100% (consistent, unaffected by food or bowel edema) 1 : 1 (20 mg PO = 20 mg IV) 20 mg

  • Bumetanide (Bumex) ~80%–90% (rapid and consistent absorption) 1 : 1 (1 mg PO = 1 mg IV) 1 mg
  • Managing Diuretic Resistance

When escalating loop diuretic doses fail to achieve adequate diuresis:

Convert Oral Furosemide to Torsemide or Bumetanide: Overcomes impaired gastrointestinal absorption caused by splanchnic venous congestion.

Implement Sequential Nephron Blockade: Combine a loop diuretic (acting at the thick ascending limb of Henle) with an oral thiazide-like diuretic such as metolazone (2.5 to 5 mg PO administered 30 minutes prior to the loop diuretic) or IV chlorothiazide. Metolazone blocks compensatory distal convoluted tubule sodium reabsorption, producing profound synergistic natriuresis. Monitor electrolytes (K+, Mg+, Na+) and renal function closely to prevent severe hypokalemic metabolic alkalosis and volume collapse.

Management of HFpEF (LVEF ≥50%) & HFmrEF (LVEF 41–49%)

Historically, pharmacotherapy for HFpEF was limited to symptom management with diuretics. Landmark randomized trials have established evidence-based disease-modifying therapies:

SGLT2 Inhibitors (Class 1 / 2a): In the EMPEROR-Preserved (empagliflozin) and DELIVER (dapagliflozin) trials, SGLT2 inhibition significantly reduced the primary composite outcome of cardiovascular death or heart failure hospitalization by ~18–21% in patients with LVEF > 40 % \text{LVEF} > 40\% LVEF > 40% . SGLT2 inhibitors are the first drug class to achieve definitive guideline endorsement across the entire spectrum of LVEF.

Mineralocorticoid Receptor Antagonists (Class 2a/2b): Spironolactone was evaluated in the TOPCAT trial; pre-specified regional analyses in the Americas showed a significant reduction in HF hospitalizations and CV mortality in symptomatic HFpEF, particularly in patients with elevated baseline BNP or LVEF at the lower end of the preserved range (45%–55%).

ARNI (Class 2a/2b): In the PARAGON-HF trial, sacubitril/valsartan showed a significant reduction in total HF hospitalizations in pre-specified subgroups, most notably in patients with LVEF ≤ 57 % \text{LVEF} \le 57\% LVEF ≤ 57% and in females.

Blood Pressure & Comorbidity Control: Rigorous systolic BP control ( < 130 mmHg <130\text{ mmHg} < 130 mmHg ), rhythm control for atrial fibrillation, weight loss, and treatment of obstructive sleep apnea are vital to prevent progressive LV stiffness and diastolic dysfunction.

Loading diagram... HFrEF GDMT Quadruple Pillar Sequencing & Optimization Algorithm